29.08 USD
+0.04 (+0.14%)
29.3 USD
+0.22 (+0.76%)
ChartMill assigns a Buy % Consensus number of 71% to MRSN. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 51. This target is 75.38% above the current price.
- MRSN was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about MRSN.
- In the previous month the buy percentage consensus was at a similar level.
- MRSN was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-11-13 | BTIG | Downgrade | Buy -> Neutral |
| 2025-11-13 | Truist Securities | Downgrade | Buy -> Hold |
| 2025-08-14 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-05-16 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-05-16 | Truist Securities | Maintains | Buy -> Buy |
| 2025-02-06 | William Blair | Initiate | Outperform |
| 2024-08-27 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-14 | Baird | Maintains | Neutral -> Neutral |
| 2024-03-19 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-02-29 | Guggenheim | Upgrade | Neutral -> Buy |
| 2024-02-29 | Wedbush | Upgrade | Neutral -> Outperform |
| 2024-02-29 | Truist Securities | Upgrade | Hold -> Buy |
| 2024-02-29 | Baird | Maintains | Neutral -> Neutral |
| 2023-12-04 | Citigroup | Upgrade | Neutral -> Buy |
| 2023-07-28 | Baird | Downgrade | Outperform -> Neutral |
| 2023-07-28 | Citigroup | Downgrade | Buy -> Neutral |
| 2023-07-27 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-07-27 | Truist Securities | Downgrade | Buy -> Hold |
| 2023-06-16 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-06-16 | Citigroup | Maintains | Buy -> Buy |
| 2023-06-15 | Guggenheim | Initiate | Buy |
| 2023-05-11 | Citigroup | Maintains | Buy |
| 2023-03-16 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2022-11-21 | Truist Securities | Initiate | Buy |
| 2022-08-09 | SVB Leerink | Maintains | Outperform |
| 2022-08-09 | Baird | Maintains | Outperform |
| 2022-05-09 | SVB Leerink | Maintains | Outperform |
| 2022-02-18 | SVB Leerink | Maintains | Outperform |
MERSANA THERAPEUTICS INC / MRSN FAQ
Can you provide the average price target for MERSANA THERAPEUTICS INC stock?
14 analysts have analysed MRSN and the average price target is 51 USD. This implies a price increase of 75.38% is expected in the next year compared to the current price of 29.08.
What is the consensus rating for MRSN stock?
The consensus rating for MERSANA THERAPEUTICS INC (MRSN) is 71.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.